Compare MEDP & WST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MEDP | WST |
|---|---|---|
| Founded | 1992 | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.1B | 18.7B |
| IPO Year | 2016 | N/A |
| Metric | MEDP | WST |
|---|---|---|
| Price | $617.55 | $250.60 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 12 | 7 |
| Target Price | ★ $479.64 | $338.00 |
| AVG Volume (30 Days) | 200.5K | ★ 744.1K |
| Earning Date | 02-09-2026 | 02-12-2026 |
| Dividend Yield | N/A | ★ 0.34% |
| EPS Growth | ★ 25.36 | 0.17 |
| EPS | ★ 14.32 | 6.75 |
| Revenue | $2,358,373,000.00 | ★ $3,017,900,000.00 |
| Revenue This Year | $21.43 | $6.97 |
| Revenue Next Year | $11.99 | $6.27 |
| P/E Ratio | $43.34 | ★ $37.79 |
| Revenue Growth | ★ 13.88 | 4.92 |
| 52 Week Low | $250.05 | $187.43 |
| 52 Week High | $628.92 | $348.90 |
| Indicator | MEDP | WST |
|---|---|---|
| Relative Strength Index (RSI) | 61.09 | 34.33 |
| Support Level | $590.00 | $244.70 |
| Resistance Level | $624.00 | $281.55 |
| Average True Range (ATR) | 19.55 | 10.13 |
| MACD | 2.03 | -3.03 |
| Stochastic Oscillator | 83.08 | 13.62 |
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.